贝莫苏拜联合安罗替尼一线治疗晚期肾透明细胞癌的成本-效用分析
葛坤坤, 朱同明, 潘旻, 易佳, 李文强, 沈爱宗
Cost-utility analysis of benmelstobart combined with anlotinib as first-line therapy for advanced clear cell renal cell carcinoma
GE Kunkun, ZHU Tongming, PAN Min, YI Jia, LI Wenqiang, SHEN Aizong
中国医院药学杂志
.
2026, (10): 1165
-1172
.
DOI: 10.13286/j.1001-5213.2026.10.10
